WILEX AG (WLXMF.PK) reported net loss of 2.6 million euros or 0.11 euros per share for the first quarter compared to the loss of 6 million euros or 0.32 euros per share a year ago.
Sales revenue for the three-month period surged to 3.7 million euros from 71 thousand euros in the prior year, mainly benefiting from sales revenue of 2.9 million euros in the Rx segment from the ongoing pro rata accrual of payments for RENCAREX.
Peter Llewellyn-Davies, chief financial officer of WILEX, stated, "We are pleased with our performance in the first quarter of 2012. The successful rights issue generated gross proceeds of EUR 9.9 million for the further funding of our studies, and we reported on several milestones and activities. Our earnings improved significantly year on year."
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org